Phase III Trial of SYHA1813 Shows Promise for High-Grade Meningiomas
A Phase III study is underway to evaluate SYHA1813 against investigator's choice treatment in high-grade meningioma patients.
Company
Pharmaceutical intelligence for SYHA Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.